Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer
This analysis generated evidence supportive of the psychometric properties of the GP5 as a fit-for-purpose measure to assess treatment tolerability in patients with advanced/metastatic MTC. The definition of "high side-effect burden" was associated with the clinical feature of tolerability.
Authors
- Marcia S. Brose (ORCID: https://orcid.org/0000-0001-7096-4057)
- Lisa M. Hess (ORCID: https://orcid.org/0000-0003-3631-3941)
- Yan Lin (ORCID: https://orcid.org/0000-0001-8034-5946)
- Angély Loubert (ORCID: https://orcid.org/0000-0002-7588-431X)
- Nalin Payakachat (ORCID: https://orcid.org/0000-0002-9526-5356)
- Antoine Regnault (ORCID: https://orcid.org/0000-0001-8234-2896)
- Patricia Maeda (ORCID: https://orcid.org/0000-0002-3377-5705)
- Rebecca M. Speck (ORCID: https://orcid.org/0000-0002-3580-117X)
- Laurine Bunod
- Adrienne M. Gilligan
Institutions
- Thomas Jefferson University (US)
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Journal of Patient-Reported Outcomes
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s41687-024-00823-8
- Citations
- 4
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.43
Funders
- Eli Lilly and Company